Human papillomavirus (HPV)

What

There are several types of human papillomavirus (HPV) that infect cutaneous and mucosal epithelial tissues. Most people clear HPV infections, but the virus persists in some cases.

Who

9vHPV (9-valent HPV) vaccine is recommended for:

• adolescents aged 9–18 years
• people with significant immunocompromising conditions (except for asplenia or hyposplenia)
• men who have sex with men

How

The recommended schedule for adolescents aged 9–14 years is 2 doses, with a 6–12-month interval between doses.

The recommended schedule for people aged ≥15 years is 3 doses, with an interval of 2 months between dose 1 and dose 2, and 4 months between dose 2 and dose 3.

The recommended schedule for people with significant immunocompromising conditions, regardless of age, is 3 doses, with an interval of 2 months between dose 1 and dose 2, and 4 months between dose 2 and dose 3.

Why

Up to 90% of the general population will be infected with at least 1 genital type of HPV at some time in their lives. People with persistent HPV infection are at risk of developing HPV-associated cancers; the most common is cervical cancer.

Human papillomavirus vaccines available in Australia

The Therapeutic Goods Administration website provides product information for each vaccine.

See also Vaccine information and Variations from product information for more details.

Dose and route

The dose of all HPV vaccines is 0.5 mL given by intramuscular injection.

2- and 3-dose schedules

People who start the HPV vaccination course at 9–14 years of age (that is, before their 15th birthday) are recommended to receive a 2-dose schedule at the following times:

• 0 (the day the 1st dose is given)
• 6–12 months

People who receive their 1st HPV vaccine dose at ≥15 years of age (that is, on or after their 15th birthday) are recommended to receive 3 doses at the following times:

• 0 (the day the 1st dose is given)
• 2 months
• 6 months

See Table. Recommended doses and intervals between doses for human papillomavirus (HPV) vaccines, by age group at the start of the course.

If the person has received doses with shorter intervals, see Table. Catch-up schedule for people ≥10 years of age (for vaccines recommended on a population level). The person may need extra doses.

Extra doses of 9vHPV vaccine

People who have completed the recommended number of doses of 2vHPV (2-valent HPV) or 4vHPV (4-valent HPV) vaccine are not routinely recommended to receive 9vHPV vaccine, because the extra benefit is thought to be marginal.

However, if the person wants protection against the additional HPV types, there appears to be no safety concerns associated with giving 9vHPV after a completed 2vHPV or 4vHPV course. ¹³ The rate of injection site reactions may increase.

Co-administration with other vaccines

HPV vaccines can be given at the same time as the following vaccines, using separate syringes and injection sites:^14-20

• dTpa (reduced antigen content diphtheria-tetanus-acellular pertussis vaccine)
• dTpa-IPV (reduced antigen content diphtheria-tetanus-acellular pertussis, inactivated poliovirus vaccine)
• hepB (monovalent hepatitis B vaccine)
• MenACWY (quadrivalent meningococcal conjugate vaccine)

There are no clinical data about co-administering HPV vaccines with varicella vaccine. Theoretically, there are no concerns about safety or efficacy if the person receives the vaccines at the same time at different injection sites.

Interchangeability of HPV vaccines

9vHPV vaccine can be used to complete an HPV vaccination schedule that was started with either the 4vHPV or the 2vHPV vaccine, as long as the appropriate minimum intervals and dose numbers are used.

HPV vaccination is generally safe and well tolerated. The safety profile and the spectrum of adverse events after vaccination in males are similar to those in females.^26,27

For all HPV vaccines, injection site reactions are the most commonly reported adverse event.^21,28,29

In most clinical trials, systemic adverse events were comparable between HPV vaccine recipients and control vaccine recipients, and included:^29,30

• headache
• fever
• nausea
• dizziness
• fatigue

Meta-analyses on both the 2vHPV and 9vHPV vaccines show no increase in the number of serious adverse events in vaccine recipients compared with control recipients.^21,31 Rates of anaphylaxis are low and consistent with rates for other vaccines.^28,32,33

Adverse events following 9vHPV compared with 4vHPV

A safety review of 7 phase III clinical trials evaluated reactions to 9vHPV vaccine and compared them with 4vHPV vaccine or placebo in males and females aged 9–26 years who received 3 doses. Serious adverse reactions were reported in <0.1% of the more than 15,000 participants.²¹ This review concluded that overall safety profiles of the 4vHPV and 9vHPV vaccines given in 3-dose schedules were similar, but found that injection site reactions were slightly more common with 9vHPV vaccine (72.5% after dose 1 of 9vHPV vaccine vs 61.0% after dose 1 of 4vHPV vaccine).

Syncope in adolescents

Post-marketing passive surveillance of HPV vaccine use has identified syncope (fainting) as a common adverse event immediately after HPV vaccination in adolescents.^28,34,36

Syncope is a benign and manageable risk of adolescent vaccination. It is likely to be a reaction to the process of vaccination, rather than to the vaccine itself. Immunisation providers should ensure that procedures are in place to minimise the risk of syncope-related falls around the time of vaccination.

See also Adverse events following immunisation.

Guillain–Barré syndrome

A 2015 French study in more than 2 million girls suggested a possible very small risk (approximately 1 in 100,000 girls vaccinated) of Guillain–Barré syndrome (GBS). However, a relationship between HPV vaccination and GBS has not been observed in any other well-conducted studies.³⁷ Ongoing research is monitoring whether there is any increased risk of GBS after HPV vaccination.

Other adverse events

Reports of various other adverse events after HPV vaccination include:

• new-onset autoimmune disease
• primary ovarian insufficiency
• complex regional pain syndrome
• postural orthostatic tachycardia

Despite these reports, there is no consistent evidence for an increased risk of these events after vaccination, or a causal relationship between these events and vaccination.^28,33

The World Health Organization’s Global Advisory Committee on Vaccine Safety,³⁸ the European Medicines Agency,³⁹ the Australian Therapeutic Goods Administration and various other key global expert vaccine groups have reviewed the evidence for a causal association between HPV vaccine and a number of these reported adverse events. These extensive reviews have not found any safety issue that would change positive recommendations for the use of the vaccine. The reviews have concluded that HPV vaccines are extremely safe.³⁷

HPV infection is often subclinical, but can cause a range of lesions depending on the infecting HPV genotype.

Low-risk HPV types

Low-risk HPV types may cause lesions such as:

• cutaneous warts
• genital warts
• respiratory papillomatosis

Anogenital warts may present as painless lumps, or with local tenderness, itching or bleeding.

Recurrent respiratory papillomatosis is potentially fatal. It is characterised by multiple warty growths on the mucosal surface of the respiratory tract.⁴⁷

Most people clear genital HPV infections (that is, the infection is no longer detectable by HPV DNA testing) within 12–24 months. However, in some cases, the virus is thought to remain as a latent infection even though DNA is no longer detectable.

In about 3–10% of infections, the virus persists. People with persistent HPV infection are at risk of developing HPV-associated cancers.^48-50

High-risk HPV types

High-risk HPV types may cause dysplasias and cancers of the:

• cervix
• vulva
• vagina
• penis
• anus
• oral cavity
• oropharynx

Dysplasias may be:

• low grade — the viral cytopathic effect of HPV infection
• high grade — precursors to cancer

Cervical cancer

The causal link between persistent cervical HPV infection and cervical cancer is well established.⁵¹

Cellular changes in the cervix as a result of HPV infection are referred to as cervical intraepithelial neoplasia. Most of these changes regress, but some will progress to cervical cancer.

Malignant transformation in the cervix usually occurs 10–20 years after infection with high-risk HPV types, but has been reported within 2 years.⁵²

Other cancers

The strength of association between HPV infection and cancers other than cervical cancer varies by site and HPV type.⁵¹

The clinical features of HPV-associated cancers and their precursor lesions depend on the anatomical site. Clinical features also vary within the oropharynx and anogenital sites other than the cervix. The progression of HPV-associated precursor lesions to cancers is less well understood in non-cervical sites than in the cervix.

2 HPV vaccines are available for use in Australia:

• 2vHPV (Cervarix), which contains virus-like particles of HPV types 16 and 18
• 9vHPV (Gardasil 9), which contains virus-like particles of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58

Virus-like particles are not infectious, and do not replicate or cause cellular abnormalities.^105,106

From 2007 to 2017, Australia’s National Immunisation Program used 4vHPV. This was replaced with 9vHPV from 2018.

Vaccine efficacy in females 16–26 years of age

Efficacy of the 2vHPV, 4vHPV and 9vHPV vaccines has been assessed in females in several international clinical trials.

2vHPV and 4vHPV vaccines

In women aged approximately 16–26 years who are naive to HPV types 16 and 18 before vaccination, the 2vHPV and 4vHPV vaccines (in a 3-dose schedule) are both about 90–100% effective at preventing type-specific persistent infection and related cervical disease.

The 4vHPV vaccine is 100% effective (95% CI: 94–100%) against vaginal and external anogenital lesions associated with HPV types 6, 11, 16 and 18 in women.^107-112

These include:

• genital warts
• vulval dysplasia
• vaginal dysplasia
• perineal dysplasia
• perianal dysplasia

The 2vHPV vaccine also provides considerable cross-protection against cervical infection with HPV types 31, 33 and 45.¹¹³

9vHPV vaccine

The 9vHPV vaccine has established efficacy (97.4%; 95% CI: 85.0–99.9%) against the following neoplasias and cancers that are associated with HPV types 31, 33, 45, 52 and 58:¹¹⁴

• cervical
• vulval
• vaginal

A clinical trial of 9vHPV vaccine in women aged 16–26 years established non-inferiority of the 9vHPV vaccine against the 4vHPV types (6, 11, 16 and 18). Incidence of disease endpoints was similarly low in women vaccinated with either 9vHPV or 4vHPV vaccine.¹¹⁴

Vaccine efficacy in males 16–26 years of age

1 clinical trial has shown the efficacy of 4vHPV vaccine in males aged 16–26 years.¹¹⁵

Vaccination was 84–100% protective against persistent anogenital infection and external genital lesions due to vaccine HPV types among HPV-naive participants.

Among HPV-naive participants in the trial, vaccine efficacy in men who have sex with men was:

• 95% against intra-anal HPV infection
• 75% against high-grade anal intraepithelial neoplasia

Efficacy of 2vHPV and 9vHPV vaccines in males has not been assessed to date. However, these vaccines have demonstrated safety and immunogenicity in adolescent and adult males.^27,27,116

Vaccine efficacy in people already infected with HPV

In women who are vaccinated regardless of their baseline HPV status (that is, women who may have pre-existing HPV infection), vaccine efficacy is lower than in HPV-naive women. This suggests reduced vaccine effectiveness among females who are already sexually active. This is because the HPV vaccines are prophylactic vaccines — they prevent primary HPV infection.

Vaccination does not:

• treat an existing HPV infection
• prevent disease that may be caused by an existing vaccine HPV-type infection^30,117-119

HPV vaccine protection is believed to be predominantly antibody mediated. Even low levels of antibodies can stop HPV entering the basal epithelial cells. HPV can only access the basal cell at sites of microtrauma, where there is a breach in the epithelium, and circulating HPV antibodies from sera are present at these sites.⁴¹

Because antibodies prevent viral entry, vaccination may still benefit sexually active men and women by protecting them against:

• new infections with other vaccine-preventable HPV types
• reinfection with vaccine-preventable types they have previously been exposed to — for example, from an infected partner
• auto-inoculation of existing persistent HPV infection to other sites

Immunogenicity in females and males <16 years of age

Pre-market trials did not assess the efficacy of HPV vaccines in females or males <16 years of age because these studies need genital samples. The trials used immunobridging studies to ensure that antibody responses in the target age of young adolescents were equivalent to those known to be protective in older women.

Young adolescents had higher antibody titres than older women.¹ Later studies confirmed that a widely spaced 2-dose HPV vaccine schedule for those aged 9–14 years at the time of the 1st dose also produced non-inferior antibody titres.¹²⁰

For the 2vHPV, 4vHPV and 9vHPV vaccines, antibody responses in pre-adolescent and adolescent females and males (>9 years of age) after 2 vaccine doses were equivalent to those in adult women, in whom clinical efficacy has been demonstrated.^1,2,121

Duration of immunity

It is currently unknown if immunity due to HPV vaccine is lifelong. However, current data support a persistent, stable antibody level after an initial plateau. Long-term population-based follow-up studies to assess this are underway. In clinical trials in women,^114,122-124 vaccine efficacy is up to:

• 6 years for 9vHPV vaccine
• 10 years for 4vHPV vaccine
• 10 years for 2vHPV vaccine

Not applicable.

1. Iversen OE, Miranda MJ, Ulied A, et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. JAMA 2016;316:2411-21.
2. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013;309:1793-802.
3. Hernández-Ávila M, Torres-Ibarra L, Stanley M, et al. Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: an epidemiological surveillance mechanism for alternate vaccination schemes. Human Vaccines and Immunotherapeutics 2016;12:30-8.
4. Romanowski B, Schwarz TF, Ferguson L, et al. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modeling predictions from a randomized study. Human Vaccines and Immunotherapeutics 2016;12:20-9.
5. Puthanakit T, Huang LM, Chiu CH, et al. Randomized open trial comparing 2-dose regimens of the human papillomavirus 16/18 AS04-adjuvanted vaccine in girls aged 9–14 years versus a 3-dose regimen in women aged 15–25 years. Journal of Infectious Diseases 2016;214:525-36.
6. Vajdic CM, van Leeuwen MT, Jin F, et al. Anal human papillomavirus genotype diversity and co-infection in a community-based sample of homosexual men. Sexually Transmitted Infections 2009;85:330-5.
7. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. The Lancet 2007;370:59-67.
8. Giuliano AR, Nyitray AG, Kreimer AR, et al. EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. International Journal of Cancer 2015;136:2752-60.
9. Giuliano AR, Lee JH, Fulp W, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. The Lancet 2011;377:932-40.
10. Daling JR, Weiss NS, Hislop TG, et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. New England Journal of Medicine 1987;317:973-7.
11. Australian Government Department of Health. Cancer screening. 2016. (Accessed Apr 2018). 
12. Brotherton JM, Wrede CD. Offering HPV vaccination to women treated for high-grade cervical intra-epithelial neoplasia: what do you need to know? [letter]. Australian and New Zealand Journal of Obstetrics and Gynaecology 2014;54:393-4.
13. Garland SM, Cheung TH, McNeill S, et al. Safety and immunogenicity of a 9-valent HPV vaccine in females 12–26 years of age who previously received the quadrivalent HPV vaccine. Vaccine 2015;33:6855-64.
14. Reisinger KS, Block SL, Collins-Ogle M, et al. Safety, tolerability, and immunogenicity of Gardasil given concomitantly with Menactra and Adacel. Pediatrics 2010;125:1142-51.
15. Vesikari T, Van Damme P, Lindblad N, et al. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatric Infectious Disease Journal 2010;29:314-8.
16. Wheeler CM, Bautista OM, Tomassini JE, et al. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 2008;26:686-96.
17. Garcia-Sicilia J, Schwarz TF, Carmona A, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women. Journal of Adolescent Health 2010;46:142-51.
18. Wheeler CM, Harvey BM, Pichichero ME, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial. Pediatric Infectious Disease Journal 2011;30:e225-34.
19. Kosalaraksa P, Mehlsen J, Vesikari T, et al. An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11–15 years of age. Pediatric Infectious Disease Journal 2015;34:627-34.
20. Schilling A, Parra MM, Gutierrez M, et al. Coadministration of a 9-valent human papillomavirus vaccine with meningococcal and Tdap vaccines. Pediatrics 2015;136:e563-72.
21. Moreira ED, Jr., Block SL, Ferris D, et al. Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase III clinical trials. Pediatrics 2016;138:e20154387.
22. Wacholder S, Chen BE, Wilcox A, et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ 2010;340:c712.
23. Descamps D, Hardt K, Spiessens B, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Human Vaccines 2009;5:332-40.
24. Garland SM, Ault KA, Gall SA, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology 2009;114:1179-88.
25. Merck Sharp & Dohme (Australia) Pty Ltd. Product information: Gardasil®9 (human papillomavirus 9-valent [types 6, 11, 16, 18, 31, 33, 45, 52, 58] vaccine, recombinant). 2017. 
26. Petäjä T, Keränen H, Karppa T, et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10–18 years. Journal of Adolescent Health 2009;44:33-40.
27. Castellsagué X, Giuliano AR, Goldstone S, et al. Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine 2015;33:6892-901.
28. Macartney KK, Chiu C, Georgousakis M, Brotherton JM. Safety of human papillomavirus vaccines: a review. Drug Safety 2013;36:393-412.
29. Angelo MG, Zima J, Tavares Da Silva F, Baril L, Arellano F. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience. Pharmacoepidemiology and Drug Safety 2014;23:456-65.
30. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New England Journal of Medicine 2015;372:711-23.
31. Angelo MG, David MP, Zima J, et al. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiology and Drug Safety 2014;23:466-79.
32. Australian Government Department of Health, Therapeutic Goods Administration. Gardasil (human papillomavirus vaccine). 24 June 2010. (Accessed Apr 2018). 
33. Phillips A, Patel C, Pillsbury A, Brotherton J, Macartney K. Safety of human papillomavirus vaccines: an updated review. Drug Safety 2017;41:329-46.
34. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302:750-7.
35. Šubelj M, Učakar V, Kraigher A, Klavs I. Adverse events following school-based vaccination of girls with quadrivalent human papillomavirus vaccine in Slovenia, 2009 to 2013. Eurosurveillance 2016;21(14):pii=30187.
36. Australian Government Department of Health, Therapeutic Goods Administration (TGA). Enhanced school-based surveillance of acute adverse events following immunisation with human papillomavirus vaccine in males and females, 2013. Version 1.0. Canberra: TGA; 2015. 
37. World Health Organization (WHO). Meeting of the Global Advisory Committee on Vaccine Safety, 7–8 June 2017. Weekly Epidemiological Record 2017;92:393-402.
38. World Health Organization (WHO), Global Advisory Committee on Vaccine Safety. Statement on safety of HPV vaccines, 17 December 2015. Geneva: WHO; 2015. 
39. European Medicines Agency (EMA). HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS. 2016. (Accessed Apr 2018). 
40. Koutsky LA, Kiviat NB. Genital human papillomavirus. In: Holmes KK, Sparling PF, Mardh PA, et al., eds. Sexually Transmitted Diseases. 3rd ed. New York, NY: McGraw-Hill; 1999.
41. Schiller J, Lowy D. Explanations for the high potency of HPV prophylactic vaccines. Vaccine 2018: [Epub ahead of print] doi:10.1016/j.vaccine.2017.12.079.
42. Serrano B, Alemany L, Tous S, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infectious Agents and Cancer 2012;7:38.
43. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infectious Agents and Cancer 2009;4:8.
44. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens. Part B: biological agents. The Lancet Oncology 2009;10:321-2.
45. Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. [erratum appears in Am J Epidemiol. 2003 May 1;157(9):858]. American Journal of Epidemiology 2003;157:218-26.
46. Tasca RA, Clarke RW. Recurrent respiratory papillomatosis. Archives of Disease in Childhood 2006;91:689-91.
47. Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. The Laryngoscope 2008;118:1236-47.
48. Giuliano AR, Harris R, Sedjo RL, et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the Young Women's Health Study. Journal of Infectious Diseases 2002;186:462-9.
49. Monsonego J, Bosch FX, Coursaget P, et al. Cervical cancer control, priorities and new directions. [erratum appears in Int J Cancer. 2004 Mar 1;108(6):945]. International Journal of Cancer 2004;108:329-33.
50. Wright TC, Jr. Natural history of HPV infections. Journal of Family Practice 2009;58(9 Suppl):S3-7.
51. World Health Organization (WHO), International Agency for Research on Cancer (IARC). IARC monographs on the evaluation of carcinogenic risks to humans. Volume 90. Human papillomaviruses. Lyon, France: IARC; 2007. 
52. Burd EM. Human papillomavirus and cervical cancer. Clinical Microbiology Reviews 2003;16:1-17.
53. Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sexually Transmitted Diseases 2014;41:660-4.
54. Richters J, de Visser R, Rissel C, Grulich A. Sex in Australia 2 summary. Australian Study of Health and Relationships (ASHR); 2014. 
55. Smith A, Agius P, Mitchell A, Barrett C, Pitts M. Secondary students and sexual health 2008: results of the 4th national survey of Australian secondary students, HIV/AIDS and sexual health. Monograph series no. 70. Melbourne: Australian Research Centre in Sex, Health and Society (ARCSHS), La Trobe University; 2009. 
56. Koutsky L. Epidemiology of genital human papillomavirus infection. American Journal of Medicine 1997;102(5 Suppl 1):3-8.
57. Garland SM, Brotherton JM, Condon JR, et al. Human papillomavirus prevalence among Indigenous and non-Indigenous Australian women prior to a national HPV vaccination program. BMC Medicine 2011;9:104.
58. Dillner J. The serological response to papillomaviruses. Seminars in Cancer Biology 1999;9:423-30.
59. Svare EI, Kjaer SK, Nonnenmacher B, et al. Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk women. Journal of Infectious Diseases 1997;176:876-83.
60. Kreimer AR, Alberg AJ, Viscidi R, Gillison ML. Gender differences in sexual biomarkers and behaviors associated with human papillomavirus-16, -18, and -33 seroprevalence. Sexually Transmitted Diseases 2004;31:247-56.
61. Newall AT, Brotherton JM, Quinn HE, et al. Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clinical Infectious Diseases 2008;46:1647-55.
62. de Pokomandy A, Rouleau D, Ghattas G, et al. Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. Journal of Infectious Diseases 2009;199:965-73.
63. Cranston RD. Anal cancer prevention: how we are failing men who have sex with men [editorial]. Sexually Transmitted Infections 2008;84:417-9.
64. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Journal of Pathology 1999;189:12-9.
65. Brestovac B, Harnett GB, Smith DW, Shellam GR, Frost FA. Human papillomavirus genotypes and their association with cervical neoplasia in a cohort of Western Australian women. Journal of Medical Virology 2005;76:106-10.
66. Stevens MP, Tabrizi SN, Quinn MA, Garland SM. Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia. International Journal of Gynecological Cancer 2006;16:1017-24.
67. Brotherton JM, Tabrizi SN, Phillips S, et al. Looking beyond human papillomavirus (HPV) genotype 16 and 18: defining HPV genotype distribution in cervical cancers in Australia prior to vaccination. International Journal of Cancer 2017;141:1576-84.
68. Australian Institute of Health and Welfare (AIHW). Burden of cancer in Australia: Australian Burden of Disease Study 2011. Australian Burden of Disease Study series no. 12. Cat. no. BOD 13. Canberra: AIHW; 2017. 
69. Australian Institute of Health and Welfare (AIHW). Cervical screening in Australia 2014–2015. Cancer series no. 105. Cat. no. CAN 104. Canberra: AIHW; 2017. 
70. Whop LJ, Garvey G, Baade P, et al. The first comprehensive report on Indigenous Australian women's inequalities in cervical screening: a retrospective registry cohort study in Queensland, Australia (2000–2011). Cancer 2016;122:1560-9.
71. Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. The Lancet 2011;377:2085-92.
72. Brotherton JM, Gertig DM, May C, Chappell G, Saville M. HPV vaccine impact in Australian women: ready for an HPV-based screening program. Medical Journal of Australia 2016;204:184-e1.
73. Grulich AE, Jin F, Conway EL, Stein AN, Hocking J. Cancers attributable to human papillomavirus infection. Sexual Health 2010;7:244-52.
74. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24 Suppl 3:S3/11-25.
75. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008;113(10 Suppl):3036-46.
76. Jin F, Stein AN, Conway EL, et al. Trends in anal cancer in Australia, 1982–2005. Vaccine 2011;29:2322-7.
77. Rubin MA, Kleter B, Zhou M, et al. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. American Journal of Pathology 2001;159:1211-8.
78. Bleeker MC, Heideman DA, Snijders PJ, et al. Penile cancer: epidemiology, pathogenesis and prevention. World Journal of Urology 2009;27:141-50.
79. Seyferth ER, Bratic JS, Bocchini JA, Jr. Human papillomavirus epidemiology and vaccine recommendations: selected review of the recent literature. Current Opinion in Pediatrics 2016;28:400-6.
80. Australian Institute of Health and Welfare (AIHW). Cancer in Australia 2017. Cancer series no. 101. Cat. no. CAN 100. Canberra: AIHW; 2017. 
81. Daling JR, Weiss NS, Klopfenstein LL, et al. Correlates of homosexual behavior and the incidence of anal cancer. JAMA 1982;247:1988-90.
82. Adelstein DJ, Ridge JA, Gillison ML, et al. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, DC. Head and Neck 2009;31:1393-422.
83. Lacau St Guily J, Jacquard AC, Prétet JL, et al. Human papillomavirus genotype distribution in oropharynx and oral cavity cancer in France – The EDiTH VI study. Journal of Clinical Virology 2011;51:100-4.
84. Smith EM, Ritchie JM, Summersgill KF, et al. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. International Journal of Cancer 2004;108:766-72.
85. Hong AM, Grulich AE, Jones D, et al. Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. Vaccine 2010;28:3269-72.
86. Hocking JS, Stein A, Conway EL, et al. Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers. British Journal of Cancer 2011;104:886-91.
87. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. Journal of Clinical Oncology 2011;29:4294-301.
88. Blomberg M, Nielsen A, Munk C, Kjaer SK. Trends in head and neck cancer incidence in Denmark, 1978–2007: focus on human papillomavirus associated sites. International Journal of Cancer 2011;129:733-41.
89. Pirotta M, Stein AN, Conway EL, et al. Genital warts incidence and healthcare resource utilisation in Australia. Sexually Transmitted Infections 2010;86:181-6.
90. Grulich AE, de Visser RO, Smith AM, Rissel CE, Richters J. Sex in Australia: sexually transmissible infection and blood-borne virus history in a representative sample of adults. Australian and New Zealand Journal of Public Health 2003;27:234-41.
91. Tortolero-Luna G. Epidemiology of genital human papillomavirus. Hematology/Oncology Clinics of North America 1999;13:245-57.
92. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clinical Infectious Diseases 2003;36:1397-403.
93. Jin F, Prestage GP, Kippax SC, et al. Risk factors for genital and anal warts in a prospective cohort of HIV-negative homosexual men: the HIM study. Sexually Transmitted Diseases 2007;34:488-93.
94. Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH. Detection of multiple human papillomavirus types in condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. Journal of Clinical Microbiology 1999;37:3316-22.
95. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006;24 Suppl 3:S3/35-41.
96. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. Journal of Infectious Diseases 2009;199:805-14.
97. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013;346:f2032.
98. Ali H, McManus H, O'Connor CC, et al. Human papillomavirus vaccination and genital warts in young Indigenous Australians: national sentinel surveillance data. Medical Journal of Australia 2017;206:204-9.
99. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. The Lancet Infectious Diseases 2011;11:39-44.
100. Fairley CK, Hocking JS, Gurrin LC, et al. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sexually Transmitted Infections 2009;85:499-502.
101. Read TR, Hocking JS, Chen MY, et al. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sexually Transmitted Infections 2011;87:544-7.
102. Derkay CS. Task force on recurrent respiratory papillomas: a preliminary report. Archives of Otolaryngology – Head and Neck Surgery 1995;121:1386-91.
103. Derkay CS. Recurrent respiratory papillomatosis. The Laryngoscope 2001;111:57-69.
104. Somers GR, Tabrizi SN, Borg AJ, Garland SM, Chow CW. Juvenile laryngeal papillomatosis in a pediatric population: a clinicopathologic study. Pediatric Pathology and Laboratory Medicine 1997;17:53-64.
105. Burk RD, Chen Z, Van Doorslaer K. Human papillomaviruses: genetic basis of carcinogenicity. Public Health Genomics 2009;12:281-90.
106. Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006;24 Suppl 3:S3/106-13.
107. Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. The Lancet 2007;369:1861-8.
108. Future I/II Study Group. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010;341:c3493.
109. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine 2007;356:1928-43.
110. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. The Lancet 2007;369:1693-702.
111. Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. [erratum appears in Lancet. 2010 Sep 25;376(9746):1054]. The Lancet 2009;374:301-14.
112. GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. The Lancet 2009;374:1975-85.
113. Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. The Lancet Infectious Diseases 2017;17:1293-302.
114. Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. The Lancet 2017;390:2143-59.
115. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. [erratum appears in N Engl J Med. 2011 Apr 14;364(15):1481]. New England Journal of Medicine 2011;364:401-11.
116. Van Damme P, Meijer CJ, Kieninger D, et al. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine 2016;34:4205-12.
117. US Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee meeting May 18, 2006. Briefing information. 2006. (Accessed Apr 2018). 
118. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New England Journal of Medicine 2007;356:1915-27.
119. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007;298:743-53.
120. D'Addario M, Redmond S, Scott P, et al. Two-dose schedules for human papillomavirus vaccine: systematic review and meta-analysis. Vaccine 2017;35:2892-901.
121. Romanowski B, Schwarz TF, Ferguson LM, et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Human Vaccines and Immunotherapeutics 2014;10:1155-65.
122. Lehtinen M, Lagheden C, Luostarinen T, et al. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point–registry-based follow-up of three cohorts from randomized trials. BMJ Open 2017;7:e015867.
123. Luna J, Plata M, Gonzalez M, et al. Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women. PLoS One 2013;8(12):e83431.
124. Nygård M, Saah A, Munk C, et al. Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine. Clinical and Vaccine Immunology: CVI 2015;22:943-8.
125. National vaccine storage guidelines: Strive for 5. 3rd ed. Canberra: Australian Government Department of Health and Ageing; 2019. https://www.health.gov.au/resources/publications/national-vaccine-storage-guidelines-strive-for-5